We demonstrated the anti-tumor activity of CB5 in multiple MYCN-induced preclinical NB models, including cell line-derived orthotopic models, both allograft and syngeneic models, and patient-derived models, suggesting that FA uptake via SLC27A2 represents an intrinsic vulnerability of MYCN-driven tumors that can be targeted therapeutically. The gene discussed is MYCN; the disease is neoplasm.